LifeMD Taps New C-Suite, Launches $299 Wegovy Bundle as Shares Tumble
By ATTN Desk · Editorial oversight: Sean Han
Introduction
LifeMD, Inc. (NASDAQ: LFMD) is a publicly traded telehealth provider founded in 1994 and rebranded in 2020. The company offers virtual consultations with board-certified physicians and nurse practitioners for primary, urgent, and chronic care. Through its LifeMD+ subscription service, members access same-day prescriptions, lab testing, weight management programs featuring GLP-1 medications, and discounts on supplements and partner services.
Corporate Structure
Headquartered at 236 5th Avenue, New York, NY, LifeMD employs between 201 and 500 people across its New York, Huntington Beach (CA), and Greenville (SC) offices. The organization operates a 50-state affiliated medical group, an integrated pharmacy network, partnerships with Quest Diagnostics and Labcorp for lab testing, and proprietary electronic medical records and call-center platforms.
Telehealth by National Cancer Institute
Developments and News
- March 17, 2025: LifeMD signed an agreement with LillyDirect’s pharmacy partner to offer Eli Lilly’s Zepbound (tirzepatide) for cash-pay patients.
- April 22, 2025: The company acquired Optimal Human Health MD, a virtual care provider focused on women's health, including hormone, metabolism, and bone-density care.
- July 31, 2025: LifeMD announced three leadership appointments: Shayna Webb Dray became Chief Operating Officer, Jacob Ellison was named Chief Analytics Officer, and Jessica Friedeman's role expanded to Chief Marketing & Product Officer.
- Late July 2025: Through a collaboration with Novo Nordisk, LifeMD launched a self-pay introductory Wegovy (semaglutide) bundle priced at $299 for the first month, including the drug at $199 and an accompanying virtual weight-loss program.
- August 5, 2025: The company filed its Form 10-Q for the quarter ended June 30, 2025.
Financial and Strategic Analysis
| Metric | Value | Date |
|---|---|---|
| Stock Price | $7.98 (−32.60%) | August 5, 2025 |
| Volume | 202,034 | August 5, 2025 |
| 52-Week Range | $3.99 – $15.84 | As of August 5, 2025 |
| Market Capitalization | $538.1 million | Yahoo Finance |
| Revenue (TTM) | $245.6 million | Yahoo Finance |
| Net Income (TTM) | −$9.0 million | Yahoo Finance |
| Profit Margin | −2.4% | Yahoo Finance |
| Cash (Q2 2025) | $36.2 million | SEC 10-Q |
Since its initial public offering in 2001, LifeMD has focused on telehealth expansion and specialty programs. Revenue grew 49% year-over-year to $65.7 million in Q1 2025, according to company disclosures. The incorporation of GLP-1 weight-management offerings and insurance acceptance in 2024 reflects a strategic move towards chronic-care services. However, stock volatility and a narrow net income margin present challenges in achieving sustainable profitability.
Market Position and Industry Context
Telemedicine demand remains elevated following broader adoption of virtual care. LifeMD competes with telehealth peers such as Hims & Hers and traditional providers entering digital channels. Partnerships with Novo Nordisk and Eli Lilly position LifeMD in the obesity-care and metabolic-wellness markets focused on GLP-1 therapeutics. The company’s integrated platform and pharmacy network aim to enhance patient access to care, while insurance acceptance and lab-testing options seek to broaden the potential customer base.
tl;dr
On July 31, 2025, LifeMD appointed new executives in operations, analytics, and marketing. In late July, it introduced a $299 self-pay Wegovy bundle in partnership with Novo Nordisk. The Q2 2025 10-Q filed on August 5 reported $36.2 million in cash and continued revenue growth, despite the share price declining 32.6% to $7.98. Upcoming events include the Q3 earnings report, expansion of GLP-1 programs, and integration of the Optimal Human Health MD platform.